search
Back to results

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Alogliptin
Placebo to alogliptin
Metformin
Pioglitazone
Sponsored by
Takeda
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Type 2 Diabetes Mellitus, Drug Therapy

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Has a historical diagnosis of Type 2 Diabetes Mellitus.
  • Has a body mass index between acceptable range.
  • Is experiencing inadequate glycemic control.
  • Body weight keeps constant.
  • Females of childbearing potential and males who are sexually active agree to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose.

Exclusion Criteria:

  • Has participated in another clinical study within the past 90 days or has received any investigational compound within 30 days prior to randomization.
  • Has a systolic blood pressure beyond the acceptable range at Screening visit.
  • Has New York Heart Association Class III or IV heart failure regardless of therapy.
  • Has any major illness or debility that in the investigator's opinion prohibits the subject from completing the study.
  • Has a history of hypersensitivity or allergies to any DPP-4 inhibitor.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Placebo Comparator

Experimental

Other

Experimental

Other

Experimental

Arm Label

Placebo

Alogliptin Monotherapy

Metformin

Metformin + Alogliptin Add-on Therapy

Pioglitazone

Pioglitazone + Alogliptin Add-on Therapy

Arm Description

Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.

Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.

Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.

Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.

Participants continued to receive their stable dose of pioglitazone with or without metformin, and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.

Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.

Outcomes

Primary Outcome Measures

Change From Baseline in Glycosylated Hemoglobin (HbA1c)
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 16. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.

Secondary Outcome Measures

Change From Baseline in HbA1c Over Time
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Weeks 4, 8 and 12. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.
Change From Baseline in Fasting Plasma Glucose Over Time
The change from Baseline in fasting plasma glucose (FPG) at Weeks 4, 8, 12 and 16. Least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline FPG as a covariate for the monotherapy, baseline FPG with baseline metformin dose as covariates for the metformin therapy, baseline FPG with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.
Percentage of Participants With Marked Hyperglycemia
Marked Hyperglycemia was defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L).
Change From Baseline in Body Weight
The change between body weight measured at Baseline and body weight measured at Weeks 8 and 16. The least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline body weight as a covariate for the monotherapy, baseline body weight with baseline metformin dose as covariates for the add-on to metformin therapy, baseline body weight with baseline metformin therapy status and baseline pioglitazone dose as covariates for the add-on to pioglitazone therapy.
Percentage of Participants With HbA1c ≤6.5% at Week 16
Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 6.5% at Week 16.
Percentage of Participants With HbA1c ≤7.0% at Week 16
Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.0% at Week 16.
Percentage of Participants With HbA1c ≤7.5% at Week 16
Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.5% at Week 16.
Percentage of Participants With a Decrease in HbA1c ≥ 0.5%
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5% at Week 16.
Percentage of Participants With a Decrease in HbA1c ≥1.0%
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.0% at Week 16.
Percentage of Participants With a Decrease in HbA1c ≥1.5%
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5% at Week 16.
Percentage of Participants With a Decrease in HbA1c ≥2.0%
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2.0% at Week 16.

Full Information

First Posted
February 1, 2011
Last Updated
February 17, 2013
Sponsor
Takeda
search

1. Study Identification

Unique Protocol Identification Number
NCT01289119
Brief Title
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes
Official Title
An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Determine the Efficacy and Safety of SYR-322 When Used in Subjects With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
February 2013
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Takeda

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to determine the efficacy of alogliptin compared to placebo when given alone or as add-on therapy to metformin or add-on to pioglitazone (with or without metformin).
Detailed Description
Diabetes is a chronic illness associated with microvascular complications such as nephropathy (kidney disease), retinopathy (eye damage) and neuropathy (nervous system damage). Diabetes is also associated with macrovascular complications including cardiovascular disease (heart disease), stroke and peripheral vascular disease (narrowing or blockage of blood vessels). These complications are associated with reduced quality of life and increased morbidity and mortality. Takeda is developing SYR-322 (alogliptin) for improvement of glycemic control in patients with Type 2 diabetes mellitus. Evaluations of alogliptin and its clinical efficacy have been conducted in multiple countries including the United States and Japan. This study will be conducted as a multi-center clinical trial in order to validate the efficacy and safety of alogliptin on type 2 diabetes population within Asia. Participants who qualified for the study were stratified into 1 of the 3 therapy groups based upon their background antidiabetic therapy before being randomized 1:1 to receive either alogliptin 25 mg once daily or matching placebo once daily. Monotherapy group - patients who had been treated with diet and exercise for at least 2 months prior to screening. Add-on to metformin therapy group - patients who had been treated with metformin for at least 3 months and at a stable dose (≥1000 mg/day) for at least 8 weeks prior to screening. Add-on to pioglitazone therapy group - patients who had been treated with a stable dose of pioglitazone alone or in combination with metformin at a stable dose for at least 8 weeks prior to screening.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Type 2 Diabetes Mellitus, Drug Therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
506 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
Arm Title
Alogliptin Monotherapy
Arm Type
Experimental
Arm Description
Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
Arm Title
Metformin
Arm Type
Other
Arm Description
Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
Arm Title
Metformin + Alogliptin Add-on Therapy
Arm Type
Experimental
Arm Description
Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
Arm Title
Pioglitazone
Arm Type
Other
Arm Description
Participants continued to receive their stable dose of pioglitazone with or without metformin, and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
Arm Title
Pioglitazone + Alogliptin Add-on Therapy
Arm Type
Experimental
Arm Description
Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.
Intervention Type
Drug
Intervention Name(s)
Alogliptin
Other Intervention Name(s)
SYR-322
Intervention Description
Alogliptin tablets
Intervention Type
Drug
Intervention Name(s)
Placebo to alogliptin
Intervention Description
Alogliptin placebo-matching tablets.
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
Fortamet, Glucophage, Glumetza
Intervention Description
Stable metformin dose
Intervention Type
Drug
Intervention Name(s)
Pioglitazone
Other Intervention Name(s)
Actos
Intervention Description
Stable pioglitazone dose
Primary Outcome Measure Information:
Title
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
Description
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 16. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.
Time Frame
Baseline and Week 16.
Secondary Outcome Measure Information:
Title
Change From Baseline in HbA1c Over Time
Description
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Weeks 4, 8 and 12. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.
Time Frame
Baseline and Weeks 4, 8 and 12.
Title
Change From Baseline in Fasting Plasma Glucose Over Time
Description
The change from Baseline in fasting plasma glucose (FPG) at Weeks 4, 8, 12 and 16. Least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline FPG as a covariate for the monotherapy, baseline FPG with baseline metformin dose as covariates for the metformin therapy, baseline FPG with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.
Time Frame
Baseline and Weeks 4, 8, 12 and 16.
Title
Percentage of Participants With Marked Hyperglycemia
Description
Marked Hyperglycemia was defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L).
Time Frame
Randomization to Week 16.
Title
Change From Baseline in Body Weight
Description
The change between body weight measured at Baseline and body weight measured at Weeks 8 and 16. The least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline body weight as a covariate for the monotherapy, baseline body weight with baseline metformin dose as covariates for the add-on to metformin therapy, baseline body weight with baseline metformin therapy status and baseline pioglitazone dose as covariates for the add-on to pioglitazone therapy.
Time Frame
Baseline and Weeks 8 and 16.
Title
Percentage of Participants With HbA1c ≤6.5% at Week 16
Description
Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 6.5% at Week 16.
Time Frame
Week 16
Title
Percentage of Participants With HbA1c ≤7.0% at Week 16
Description
Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.0% at Week 16.
Time Frame
Week 16
Title
Percentage of Participants With HbA1c ≤7.5% at Week 16
Description
Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.5% at Week 16.
Time Frame
Week 16
Title
Percentage of Participants With a Decrease in HbA1c ≥ 0.5%
Description
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5% at Week 16.
Time Frame
Baseline and Week 16
Title
Percentage of Participants With a Decrease in HbA1c ≥1.0%
Description
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.0% at Week 16.
Time Frame
Baseline and Week 16
Title
Percentage of Participants With a Decrease in HbA1c ≥1.5%
Description
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5% at Week 16.
Time Frame
Baseline and Week 16.
Title
Percentage of Participants With a Decrease in HbA1c ≥2.0%
Description
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2.0% at Week 16.
Time Frame
Baseline and Week 16.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Has a historical diagnosis of Type 2 Diabetes Mellitus. Has a body mass index between acceptable range. Is experiencing inadequate glycemic control. Body weight keeps constant. Females of childbearing potential and males who are sexually active agree to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose. Exclusion Criteria: Has participated in another clinical study within the past 90 days or has received any investigational compound within 30 days prior to randomization. Has a systolic blood pressure beyond the acceptable range at Screening visit. Has New York Heart Association Class III or IV heart failure regardless of therapy. Has any major illness or debility that in the investigator's opinion prohibits the subject from completing the study. Has a history of hypersensitivity or allergies to any DPP-4 inhibitor.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Professor Study Chair
Organizational Affiliation
Takeda
Official's Role
Study Chair
Facility Information:
City
Beijing
State/Province
Beijing
Country
China
City
Fuzhou
State/Province
Fujian
Country
China
City
Xiamen
State/Province
Fujian
Country
China
City
Guangzhou
State/Province
Guangdong
Country
China
City
Haikou
State/Province
Hainan
Country
China
City
Ha'erbin
State/Province
Heilongjiang
Country
China
City
Jingzhou
State/Province
Hubei
Country
China
City
Shiyan
State/Province
Hubei
Country
China
City
Changsha
State/Province
Hunan
Country
China
City
Wuxi
State/Province
Jiangsu
Country
China
City
Nanchang
State/Province
Jiangxi
Country
China
City
Changchun
State/Province
Jilin
Country
China
City
Shenyang
State/Province
Liaoning
Country
China
City
Jinan
State/Province
Shandong
Country
China
City
Shanghai
State/Province
Shanghai
Country
China
City
Xi'an
State/Province
Shanxi
Country
China
City
Tianjin
State/Province
Tianjin
Country
China
City
Kunming
State/Province
Yunnan
Country
China
City
Hangzhou
State/Province
Zhejiang
Country
China
City
Hong Kong
Country
Hong Kong
City
Taipei County
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes

We'll reach out to this number within 24 hrs